Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy

Abstract

Current non-invasive approaches for detection of urothelial cancers are suboptimal. We developed a test to detect urothelial neoplasms using DNA recovered from cells shed into urine. UroSEEK incorporates massive parallel sequencing assays for mutations in 11 genes and copy number changes on 39 chromosome arms. In 570 patients at risk for bladder cancer ( BC), UroSEEK was positive in 83 of those who developed BC. Combined with cytology, UroSEEK detected 95 of patients who developed BC. Of 56 patients with upper tract urothelial cancer, 75 tested positive by UroSEEK, including 79 of those with non-invasive tumors. UroSEEK detected genetic abnormalities in 68 of urines obtained from BC patients under surveillance who demonstrated clinical evidence of recurrence. The advantages of UroSEEK over cytology were evident in low-grade BCs; UroSEEK detected 67 of cases whereas cytology detected none. These results establish the foundation for a new non-invasive approach for detection of urothelial cancer.